Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 36, Issue -, Pages 555-565Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0360555
Keywords
arabinogalactan; biosynthesis; cell wall; drug target; Mycobacterium tuberculosis; mycolic acid
Categories
Funding
- Royal Society Wolfson Research Merit Award
- Medical Research Council
- The Wellcome Trust [081569/Z/06/7]
- Career Development Award
- Medical Research Council [G9901077, G0600105] Funding Source: researchfish
- MRC [G9901077, G0600105] Funding Source: UKRI
Ask authors/readers for more resources
In spite of effective antibiotics to treat TB (tuberculosis) since the early 1960s, we enter the new millennium with TB currently the leading cause of death from a single infectious agent, killing more than 3 million people worldwide each year. Thus an understanding of drug-resistance mechanisms, the immunobiology of cell wall components to elucidate host-pathogen interactions and the discovery of new drug targets are now required for the treatment of TB. Above the plasma membrane is a classical chemotype IV pepticloglycan to which is attached the macromolecular structure, mycolyl-arabinogalactan via a unique diglycosylphosphoryl bridge. The present review discusses the assembly of the mAGP (mycolyl-arabinogalactan-peptidoglycan) complex and the site of action of EMB (ethambutol), bringing forward a new era in TB research and focus for new drugs to combat multidrug-resistant TB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available